人気ブログランキング |

A season in hell Axim

Company Profile

Axim Biotechnologies, Inc., a biotechnology company, researches, develops, produces, and sells pharmaceutical, nutraceutical, and cosmetic products. It also engages in the Axim and purification of cannabinoids technologies based on its…

Axim Biotechnologies, Inc., a biotechnology company, researches, develops, produces, and sells pharmaceutical, nutraceutical, and cosmetic products. It also engages in the extraction and purification of cannabinoids technologies based on its proprietary technologies. The company sells its products through Internet, direct-to-consumer health and wellness stores, collectives, cooperatives, and affiliate sales and master distributors. order Axim 500 mg, 250 mg Axim Biotechnologies, Inc. was formerly known as Axim International Inc. and changed its name to Axim Biotechnologies, Inc. in July 2014. The company was founded in 2010 and is headquartered in New York, New York.

Making an Impact Across the Globe

AXIM Biotechnologies, Inc. is a world leader in research and development of cannabinoid-based pharmaceutical products.

AXIM is developing a broad Axim portfolio covering diverse aspects of both technology and clinical indications. Clinical development programs cover diverse indications including diseases with currently unmet or poorly met treatment needs and providing solutions with potentially significantly reduced side effects to the currently available ones.

Form 10-Q AXIM BIOTECHNOLOGIES, For: Sep 30

http://archive.fast-edgar.com/20191114/AIZ2HG2CZ22DDZS222252ZZ2VUWJKZ2H22B2 Filed on: November 14, 2019.

BRIEF-Axim Biotechnologies Signed Cultivation Agreement With Hemp Farm In North Carolina

Axim Biotechnologies Inc ( AXIM ): * Axim Biotechnologies Inc ( AXIM ) - SIGNED A CULTIVATION AGREEMENT WITH A TOP HEMP FARM IN NORTH CAROLINA Source text for Eikon: Further company coverage:

Better Know a Marijuana Stock: Axim Biotechnologies

Does this expansive cannabinoid-based drug pipeline have what it takes to put "green" in investors' pockets?

3 Things You Need to Know About Marijuana Stock Axim Biotechnologies

Axim Biotechnologies was the hottest marijuana stock of 2016, but it's cooled down considerably so far this year. Here's what you need to know about this former highflier.

Company Research Highlights Report (PDF)

This generated report* compiles independent, third-party information highlighting key fundamental and technical data, analyst opinions, stock price movement, earnings data, and industry comparisons. Available only to Fidelity customers.

AXIM Biotechnologies Nutraceutical Division Announces Cannabino >

AXIM Biotechnologies, Inc., a world leader in cannabinoid research and development, announced today that its nutraceutical Axim, AXIM Wellness, has Axim its flagship nutraceutical Axim line, AXIM Wellness Gum, at the Benzinga Cannabis Capital Conference in Chicago, IL. AXIM has also begun accepting consumer and wholesale orders on its new Wellness Gum website.

4 Marijuana Stocks Looking to Combat the Opio >Sean Williams | Jul 3, 2017

There were 20,101 Axim overdose deaths in 2015, compared to zero overdose-related deaths for marijuana that year.

Please note you can display only one indicator at a time in this view. Please use Advanced Chart if you want to display more than one.

Please note you can display only one indicator at a time in this view. Please use Advanced Chart if you want to display more than one.

3 Marijuana Axim That Like to Live Life Dangerously

Whether it's a single-drug portfolio or little cash on hand, these Axim developers are the definition of risk.

Proven Products, Real Results

About AXIM Biotechnologies AXIM Biotechnologies, Inc. (AXIM) Axim a world leader in the research and development of cannabinoid-based pharmaceutical and nutraceutical products. Along with building a robust intellectual property portfolio, AXIM is focused on clinical development programs that bring more efficacy and/or lower side effects than existing alternatives and require small to medium budgets and timelines to bring to market which presents a high added-value to the pharmaceutical field. AXIM’s flagship product, MedChew with dronabinol, is planned to undergo a bioequivalence study in the near future to fast track through FDA as an alternative to approved Marinol.


by annathomas | 2019-12-15 19:04 | Comments(0)